CISO compensation packages in North America saw strong growth this year, but security budget increases hit their slowest pace in five years. The gap between top earners and median CISOs remains dramatic, with the top 1% making over $3.2 million.
Michael Burry, famous for his ‘Big Short’ bet against housing, has terminated his hedge fund’s registration. The SEC database shows Scion Asset Management’s status as terminated effective November 10. Burry hinted at “much better things” coming November 25th.
DartPoints is pouring $125 million into expanding its South Carolina data center footprint. The project will transform the Greenville facility from 2.5MW to 12.5MW capacity with high-density capabilities. This represents one of the company’s first major expansions since its 2021 merger with Immedion
BioNTech has officially stated that its partnership with Pfizer remains unchanged following reports that Pfizer might be looking to sell its stake. The German biotech firm declined to comment on Pfizer’s potential capital market activities while emphasizing their ongoing collaboration.
The South Wales-based compound semiconductor cluster CSconnected has launched a £1 million third call in its Supply Chain Development Programme. The initiative aims to accelerate supply chain expansion with grants up to £100,000 for UK-based companies. Projects must run between six and nine months a
In a new book excerpt, Adam Grant reflects on pandemic data interpretation and the human side of numbers. He argues we need more emotional connection to data in uncertain times.
Zilch has raised $175 million in equity and debt funding led by KKCG. The BNPL startup maintains its $2 billion valuation and plans to pursue strategic acquisitions while preparing to launch Zilch Pay next year.
Elon Musk’s X faces another EU investigation, this time focused on whether users can properly appeal content moderation decisions. The probe could lead to fines up to 6% of global revenue if violations are found.
Cinven’s CEO Supraj Rajagopalan faces potential disqualification from running UK companies over a pharmaceutical pricing scandal. The same deal that propelled him to leadership in 2015 now threatens to end his career. Regulators found Advanz Pharma gouged the NHS with excessive drug prices during Ci
Federal regulators are investigating proxy advisory giants ISS and Glass Lewis for potential antitrust violations. The move comes as the Trump administration considers broader action against firms influencing corporate America’s direction.
